Beer drinkers beware: Scientists find 'forever chemicals' exceeding EPA limits in American brews
A team from the ACS' Environmental Science & Technology conducted a study to find out how polyfluoroalkyl substances (PFAS) or "forever chemicals" get into beers and how much they contain.
"As an occasional beer drinker myself, I wondered whether PFAS in water supplies was making its way into our pints. I hope these findings inspire water treatment strategies and policies that help reduce the likelihood of PFAS in future pours," research lead Jennifer Hoponick Redmon said.
Alcohol Deaths Have More Than Doubled In Recent Years, Especially Among Women
While breweries have water filtration and treatment systems, these are not designed to prevent PFAS from entering into the batch.
By modifying an EPA testing tool for analyzing levels of PFAS in drinking water, Redmon and her team tested 23 beers.
Read On The Fox News App
Not Only Does Beer Taste Great, There Are Health Benefits Associated With It, Too: Expert
The team tested beers from areas with known documented water system contamination along with some other popular beers with unknown water sources.
Through their research, it was found that beer brewed in North Carolina, California, and Michigan had elevated levels of this PFAS.
The researchers found a strong correlation between PFAS concentrations in municipal drinking water and levels in locally brewed beer.
In 95% of the beer tested, PFAS was found with perfluorooctanesulfonate and perfluorooctanoic acid, two forever chemicals with recently established EPA limits in drinking water.
International beers tested — one from Holland and two from Mexico — were less likely to have detectable PFAS.
"Our findings indicate a strong link between PFAS in drinking water and beer, with beers brewed in areas with higher PFAS in local drinking water translating to higher levels of PFAS in beer, showing that drinking water is a primary route of PFAS contamination in beer," the research team concluded.Original article source: Beer drinkers beware: Scientists find 'forever chemicals' exceeding EPA limits in American brews
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
2 hours ago
- Fox News
Beach bacteria warnings plague Fourth of July weekend plans nationwide
Americans heading to the beach for Independence Day weekend may want to check if the waters are OK for swimming or wading. Warnings of high bacteria levels from public health officials have begun popping up in various states coast to coast. Vibrio is a bacterium that naturally lives in coastal waters, causing fever, vomiting, diarrhea, and cramps, according to the U.S. Centers for Disease Control and Prevention (CDC). On the West Coast, California officials in San Diego issued many warnings and closures of popular beaches, noting that some "bacteria levels exceed health standards." Two counties in Long Island, New York, have issued similar advisories. Suffolk County health officials posted, "Benjamin Beach in Bay Shore, Ronkonkoma Beach in the Town of Islip, and Sayville Marina Park Beach in Sayville are closed to bathing due to the finding of bacteria at levels in excess of acceptable criteria." The beaches will reopen when further testing reveals bacteria levels have dropped to acceptable levels, said the press release. Three Nassau County beaches — Hewlett Point, Island Park, and Phillip Healey Beach — are under advisory after heavy rainfall, according to the Nassau County Department of Health (NCDOH). Beaches will reopen when further testing reveals bacteria levels have dropped to acceptable levels. "Stormwater runoff may have impacted water quality at 3 South Shore beaches. As a precaution, NCDOH is advising against swimming at these locations. Stormwater runoff can raise bacteria levels, possibly exceeding NYS standards for safe bathing," said an NCDOH press release. In Massachusetts, nearly 20 beaches were closed as of Wednesday morning. Seventeen beaches are listed on the Massachusetts Department of Health "Beaches Dashboard," due to bacteria levels. Washington state lists advisories to "stay out of the water" at seven beaches with "high bacteria" in King County, according to its website. The Prairie State lists 34 advisories on their Illinois government website. There are 80,000 cases of the infection reported each year, according to the CDC. Michigan has nine beaches closed due to high bacteria levels from "wildlife" and "storm water runoff." Four beaches in the Great Lake State also have contamination advisories.
WIRED
2 hours ago
- WIRED
With RFK Jr. in Charge, Insurers Aren't Saying If They'll Cover Vaccines for Kids If Government Stops Recommending Them
Jul 2, 2025 10:25 AM RFK Jr.'s vaccine advisory board could stop recommending some routine childhood immunizations, leaving insurers to decide whether to still cover them. For now, most are remaining tight-lipped. Photograph:In the wake of the Advisory Committee on Immunization Practices (ACIP) announcing plans to revisit its recommended schedule for childhood vaccinations—a move that has drawn widespread criticism from experts—major insurers have not confirmed whether they'll continue to cover the full cost of routine shots for children. For 60 years ACIP has provided vaccine guidance to the Centers for Disease Control and Prevention (CDC), including on the timing and dosage of childhood immunizations. Insurers are required to cover the cost of most jabs on the recommended schedule for children. On Wednesday June 25, ACIP announced it would review the schedule, just weeks after health secretary and longtime anti-vaccine activist Robert F. Kennedy Jr. replaced the entire committee with his own appointees. When WIRED then asked 21 of the country's largest health insurance groups whether they would stop providing cost-free coverage of current routine immunizations in the event ACIP stops recommending them, only Blue Shield of California—a company in the Blue Cross Blue Shield Association—confirmed it would. 'As a payer our role is to ensure ongoing coverage and access to preventive, evidence-based care, including immunizations,' says company spokesperson Mark Seelig. 'Therefore, Blue Shield of California is committed to maintaining coverage of immunizations. The decision on whether to receive a vaccine is between our member and their provider.' Other large insurers, including UnitedHealthcare (which provides coverage for 50 million people), Cigna, Kaiser Permanente, Anthem, Humana, and Centene Corporation, did not respond to requests for comment. Blue Cross Blue Shield of Michigan said it had no comment. Most insurers that did respond said they were keeping an eye on developments in Washington, without indicating whether they would or would not cover vaccines dropped from the recommended schedule. 'Vaccines play an important role in the prevention of more serious illnesses,' says Phil Blando, a spokesperson at CVS Health, which owns the insurer Aetna. 'We are monitoring any changes the federal government makes to vaccination guidance and eligibility and will evaluate whether coverage adjustments are needed.' Highmark Inc., part of the Blue Cross Blue Shield Association, operating in Pennsylvania, Delaware, West Virginia, and New York, is also waiting to see what decision ACIP reaches. 'We are closely monitoring the evolving vaccine discussions occurring in Washington, DC. Various vaccines and immunizations are covered under Highmark's member benefits, with any future coverage considerations to be evaluated as more information becomes available,' says spokesperson Aaron Billger. Bryan Campen, of Health Care Service Corporation—the licensee of Blue Cross Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas—notes that no changes have yet been made to the vaccines ACIP recommends or the company's vaccine coverage, but says that the company will 'continue to monitor any activity that may impact preventive care recommendations and will communicate any changes to recommendations that may impact standard coverage of preventive services.' Insurers had an eye on changes in ACIP guidance even before the committee announced it would revisit the schedule. 'As we navigate an evolving health care landscape, maintaining robust immunization coverage continues to be a top priority for protecting both individual and community health,' the industry's trade association, AHIP, said in a June 24 statement, the day before ACIP's announcement. 'We are committed to ongoing coverage of vaccines to ensure access and affordability for this respiratory virus season,' the statement continued. 'We encourage all Americans to talk to their health care provider about vaccines.' ACIP made headlines in early June when RFK Jr. fired all 17 of its members and replaced them with eight new appointees. (The HHS secretary appoints the committee's members, but conventionally they serve fixed 4-year terms.) These new appointees include Retsef Levi, who has stated—in the face of scientific consensus—that mRNA vaccines are deadly, and Robert Malone, who routinely shares articles about supposed links between cancer and the Covid vaccine, which no credible research has found to exist. Neither Levi nor Malone replied to a request for comment. Michael A. Ross, another recently appointed committee member, resigned from ACIP during a review of his financial holdings, the New York Times reported on June 24. When introducing his new ACIP appointees in a post on X earlier in June, RFK Jr. had described Ross as a faculty member at George Washington and Virginia Commonwealth universities—but spokespeople for the universities told NBC News4 that Ross had not taught at either in years. Ross did not reply to a request for comment. The committee made news again on June 25 when, during its first meeting of the year, it announced it would form a working group to review the recommended immunization schedule for children and teens. 'The number of vaccines that our children and adolescents receive today exceed what children in most other developed nations receive, and what most of us in this room received when we [were] children,' ACIP chair Martin Kulldorff said during the meeting. He noted that the group would examine the 'cumulative effect' of the recommended vaccine schedule, including interactions between vaccines, the total number of vaccines given, their timing, and recipients' exposure to vaccine ingredients. But the process for adding vaccines to the schedule is already rigorous. Before a vaccine can receive FDA licensure, its manufacturer must prove it does not negatively affect the safety or immune response of other vaccines administered at the same time on the schedule, says Paul Offit, director of the Children's Hospital of Philadelphia's Vaccine Education Center. In addition, 'the notion that these vaccines are somehow weakening your immune system or overwhelming your immune system is fanciful,' Offit says. Today, children are exposed to fewer viral or bacterial proteins in the first few years of the vaccine schedule than those in earlier generations. When Offit's parents received the smallpox vaccine, they were exposed to 200 proteins in a single shot. In contrast, the measles vaccine only contains 10. During the meeting, Kulldorff repeated claims he made in 2024 that he was fired from Harvard because he refused to get the Covid vaccine; he and Malone have also each served as paid expert witnesses in two separate suits against Merck over the safety of the company's HPV vaccine and its mumps vaccine, respectively. Kulldorff did not reply to a request for comment. The American Academy of Pediatrics (AAP) did not send representatives to last week's ACIP meeting, as it typically does. According to Academy president Susan Kressly, this was because the AAP believes the vaccine recommendation process lost credibility when its original membership was gutted by Kennedy. 'We won't lend our name or our expertise to a system that is being politicized at the expense of children's health,' Kressly said in a video posted online before the meeting was set to begin. The AAP did not reply to a request for comment about the video. The most recent child immunization schedule that the AAP endorses, from November 2024, is posted on the AAP website. A newer one, posted on the CDC site, has already changed recommendations. It no longer lists as 'routine' Covid vaccines for children under 18 who are not immunocompromised, but instead lists them under vaccines recommended for 'shared clinical decision-making,' informed by 'personal preference and circumstances.' The change should not affect insurance coverage.
Yahoo
2 hours ago
- Yahoo
Medical Exoskeleton Market Poised for Growth, Estimated to Hit USD 2,267.2 Million by 2032
The Medical Exoskeleton Market presents strong opportunities due to growing demand for rehabilitation solutions, rising spinal cord injury cases, advances in robotic technology, and increased adoption in elderly care and physical therapy settings Burlingame, CA, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Medical Exoskeleton Market is estimated to be valued at USD 538.4 Mn in 2025 and is expected to reach USD 2,267.2 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 22.8% from 2025 to 2032. Medical exoskeletons are wearable systems designed to support movement and enhance physical strength. These devices assist individuals with mobility challenges such as muscle weakness or spinal injuries in walking, standing, lifting, and participating in rehabilitation or work-related tasks. Market growth is fueled by the rising number of spinal cord injuries, increasing orthopaedic conditions, and the expanding elderly population. Request Sample Report: Global Medical Exoskeleton Market Key Takeaways According to Coherent Market Insights (CMI), the global medical skeleton market size is expected to grow more than fourfold, from USD 538.4 Mn in 2025 to USD 2,267.2 Mn by 2032. Global demand for medical exoskeletons is anticipated to increase at a prolific CAGR of 22.8% during the forecast period. Based on type, lower body exoskeletons segment is expected to dominate the industry, holding a market share of 43.2% in 2025. North America is projected to account for nearly two-fifths of the global medical exoskeleton market share in 2025. Europe medical exoskeleton market is estimated to be valued at around USD 150. 75 Mn by 2025. Asia Pacific is poised to record fastest growth during the assessment period. This is due to rising incidence of mobility impairments and disabilities, as well as increasing acceptance and adoption of medical exoskeletons. Get Instant Access! Purchase Research Report and Receive a 25% Discount: Rising Prevalence of Disabilities and Neurological Disorders Fueling Market Growth Coherent Market Insights' latest global medical exoskeleton market research report provides insights into key factors driving the industry's growth. One such key growth driver is the increasing incidence of neurological disorders and physical disabilities. According to the World Health Organization (WHO), over 3 billion people worldwide are living with a neurological condition. This rise in neurological disorders like stroke, multiple sclerosis, Parkinson's disease, and cerebral palsy is expected to boost demand for medical exoskeletons. Medical exoskeletons are designed to assist or enhance human movement. They have the tendency to support rehabilitation by assisting weakened muscles. These wearable mechanical devices consist of structural components, control systems, sensors, motors, and actuators that work together to mimic human motion. High Cost and Regulatory Hurdles Limiting Market Growth The global medical exoskeleton market outlook indicates strong future growth. However, high cost of medical exoskeletons and regulatory challenges are expected to limit market expansion to some extent. Advanced medical exoskeletons are quite expensive, costing thousands of dollars. This high cost deters patients with disabilities from opting for medical exoskeletons, leading to reduced market demand. Similarly, medical exoskeletons must undergo rigorous and often lengthy regulatory approval processes. These processes can delay product launches and increase development costs, potentially hindering the global medical exoskeleton market growth. Ongoing Innovations Creating Lucrative Growth Opportunities Innovation remains a prime area of focus for medical exoskeleton companies to capitalize on emerging opportunities. Leading industry players are constantly integrating AI, IoT, sensors, and lightweight materials in their products to enhance functionality, comfort, and adaptability of medical exoskeletons. Similarly, advancements in battery technologies and wearable designs are making medical exoskeletons more attractive, accessible, and user-friendly. These innovations are expected to play a key role in boosting the overall global medical exoskeleton market value during the forecast period. Impact of AI on the Global Medical Exoskeleton Market Artificial intelligence (AI) is creating strides in the global medical exoskeleton market. This advanced technology is transforming rigid assistive devices into adaptive, intelligent companions. AI enables exoskeletons to anticipate users' intentions as well as deliver real-time motion adjustments and reduce fall risk. This heightened responsiveness is particularly beneficial in rehabilitation. AI-enabled remote monitoring and cloud integration allow clinicians to track progress and adjust protocols virtually. This technology helps extend rehabilitation and mobility support beyond traditional healthcare settings, thereby unlocking new growth opportunities in the medical exoskeleton market. Emerging Global Medical Exoskeleton Market Trends Increasing geriatric population is expected to uplift demand for medical exoskeletons, as older adults are more susceptible to mobility impairments and musculoskeletal conditions like osteoporosis and arthritis. This demographic shift is increasing the need for effective rehabilitation solutions and mobility assistance technologies. Rising cases of spinal cord injuries is positively impacting sales of medical exoskeletons. As more people suffer from spinal cord injuries, they need assistive and rehabilitative technologies like medical exoskeletons. These technologies play a crucial role in supporting mobility, enhancing rehabilitation outcomes, and improving quality of life for individuals with spinal cord injuries. There is a rapid transition from stationary exoskeletons to mobile ones. Companies are striving to develop mobile medical exoskeletons to meet evolving needs and preferences of end users. Leading companies are also focusing on developing exoskeletons for home care settings. This will likely contribute to the expansion of the global medical exoskeleton industry in the coming years. Get Customization on this Report: Analyst's View said Manisha Vibhute, a senior analyst at CMI. Current Events and Their Impact on the Global Medical Exoskeleton Market Event Description and Impact U.S. Department of Veterans Affairs Expands Exoskeleton Coverage Description: The U.S. Department of Veterans Affairs has expanded reimbursement eligibility for powered exoskeletons used in spinal cord injury rehabilitation. Impact: This move is expected to open a significant reimbursement pathway, increasing accessibility for U.S. veterans and encouraging wider adoption of exoskeletons in hospitals and rehabilitation centers. Breakthroughs in Exoskeleton Technologies Description: In February 2025, Chulalongkorn University introduced its 'Exoskeleton Wheelchair,' a hybrid robotic suit designed to assist elderly individuals and people with mobility challenges in sitting, standing, and walking. Impact: Such technological advancements are likely to accelerate innovation and fuel market growth in the medical exoskeleton industry. European Union's AI Act Implementation Begins Description: The EU started phased enforcement of the AI Act, with medical AI-powered devices classified under strict regulatory scrutiny. Impact: Companies developing AI-integrated exoskeletons must comply with rigorous transparency and safety criteria. Competitor Insights Key companies listed in the global medical exoskeleton market report: BIONIK ReWalk Robotics Ekso Bionics Suit X PARKER HANNIFIN CORP Rex Bionics Ltd B-Temia CYBERDYNE INC. ExoAtlet Wandercraft Key Developments In April 2025, Lifeward Ltd. announced the U.S. launch of the ReWalk 7 Personal Exoskeleton for people with spinal cord injuries. The new device, featuring enhanced features, is designed to provide a more functional and personalized walking experience. In February 2025, Wandercraft initiated a new clinical trial for its groundbreaking Personal Exoskeleton at the James J. Peters VA Medical Center in the Bronx, NY. It is the world's first self-balancing exoskeleton developed for personal use. In December 2024, researchers at the Korea Advanced Institute of Science and Technology developed a lightweight wearing robot for paraplegic patients. The new Iron Man Robot, named WalkON Suit F1, can approach paraplegic patients and lock itself onto them, enabling them to walk, climb staircases, and maneuver obstacles. Global Medical Exoskeleton Market Segmentation: By Type Lower Body Exoskeletons Upper Body Exoskeletons Full Body Exoskeletons Others (Soft Exoskeletons, Active Exoskeletons, Passive Exoskeletons) By Mobility Mobile Exoskeletons Stationary Exoskeletons Fixed Exoskeletons By End User Rehabilitation Centers Hospitals Long Term Care Centers Homecare Settings Others (Industrial Sites, Military) By Region North America Europe Asia Pacific Latin America Middle East and Africa Read More Reports: Bionic Prosthetics Market Size, Share & Trend Analysis Report (2025-2032)Exoskeleton Market Size, Share, Trends & Opportunities for 2025 to 2032Military Exoskeleton Market Analysis and Forecast for 2025-2032 Our Trusted Partners:Worldwide Market Reports, Coherent MI, Stratagem Market InsightsGet Recent News: CONTACT: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Contact Us: Mr. Shah Coherent Market Insights 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States US: + 12524771362 UK: +442039578553 AUS: +61-2-4786-0457 India: +91-848-285-0837 Email: sales@ Website: For Latest Update Follow Us: LinkedIn | Facebook | Twitter
